A new activating mutation of CASR gene leads to a truncated tail. The in-vitro study shows that mutated receptor is more active than the wild-type. The patient had a prolonged QTc, but no clinical signs of hypocalcemia. No nephrocalcinosis was present despite high renal calcium excretion. The treatment did not normalized serum calcium and renal calcium excretion.